Clinical stage immune therapy vaccine for threatment of HIV.
The information set forth below may not be exhaustive and does not imply any elements of a contractual relationship. While we make every effort to ensure that any material in this whitepaper is accurate and up to date, such material in no way constitutes the provision of professional advice. DVT (Dermavir Token) does not guarantee, and accepts no legal liability whatsoever arising from or connected to, the accuracy, reliability, currency, or completeness of any material contained in this white paper. Investors and potential DVT token holders should seek appropriate independent professional advice prior to relying on or entering into any commitment or transaction based on, material published in this white paper, which material is purely published for reference purposes alone. DVT tokens will not be intended to constitute securities in any jurisdiction. This whitepaper does not constitute a prospectus or offer document of any sort and is not intended to constitute an offer of securities or a solicitation for investment in securities in any jurisdiction. DVT does not provide any opinion on any advice to purchase, sell, or otherwise transact with DVT tokens and the fact of presentation of this white paper shall not form the basis of, or be relied upon in connection with, any contract or investment decision. No person is bound to enter into any contract or binding legal commitment in relation to the sale and purchase of DVT tokens, and no cryptocurrency or any other form of payment is to be accepted on the basis of this white paper.